Skip to main content
OpenTrials
Completed

NCT Number: NCT01501591

Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size

The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their possible interaction. Current interpretation of the results of clinical trials (the gold standard in evidence based medicine) assumes no such interaction. Using a novel cross-over balanced placebo design and caffeine as a model drug, the investigators have recently shown that a negative interaction does exist; suggesting that the size of drug effect as currently measured by clinical trials may not be accurate. Due to the novelty of the findings and their important clinical practice and research implications, they need to be confirmed using another drug; and the size of drug effect measured using the novel design need to be directly compared to that measured using conventional clinical trial design. The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and help assess the appropriateness of randomized clinical trials in determining the size of drug effect.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King Faisal Specialist Hospital & research Center

Riyadh, 11211, Saudi Arabia

About this study

BACKGROUND:

The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their possible interaction. Current interpretation of the results of clinical trials (the gold standard in evidence based medicine) assumes no such interaction. Using a novel cross-over balanced placebo design and caffeine as a model drug we have recently shown that a negative interaction does exist; suggesting that the size of drug effect as currently measured by clinical trials may not be accurate. Due to the novelty of the findings and their important clinical practice and research implications, they need to be confirmed using another drug; and the size of drug effect measured using the novel design need to be directly compared to that measured using conventional clinical trial design.

DESIGN:

A cross-over balanced placebo plus randomized placebo-controlled clinical trial design.

METHODS:

480 adults will be double-blindly randomized to three groups: first generation H-1 receptor antagonist- hydroxyzine (25 mg), placebo, or hydroxyzine+placebo group. The first two groups will receive the assigned intervention described by the investigators as hydroxyzine or placebo, in a randomized crossover design. The third group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design. Group assignment will be concealed from volunteers and recruiters. Data collectors will be blinded to group assignment and intervention assignment. Volunteers will be partially deceived to the intervention assignment in the first two groups and blinded in the third group. The interventions to the third group will be also administered blindly. Serum hydroxyzine levels will be determined 3 hours post intervention from all volunteers to verify compliance and help maintain deception/blinding. The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and help assess the appropriateness of randomized clinical trials in determining the size of drug effect.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age of 18 to 50 years;
  • Being healthy,
  • Able to abstain from smoking and alcohol
  • Medication-free for one week
  • Able to reproducibly express oneself using a 100 mm visual analog scale (VAS).

Exclusion criteria

  • clinically relevant deviation from normal health
  • pregnancy or lactation
  • hypersensitivity to hydroxyzine or related compounds

Treatment and study plan

Hydroxizine

Drug

25 mg orally, one time on two different days, 72 hours apart

Placebo

Other

Matching placebo once on two different days, 72 hours apart.

hydroxyzine/placebo

Drug

25 mg hydroxyzine or placebo once on two different days, 72 hours apart

Primary outcomes

  1. Area-under-the-curve for drowsiness

    Time frame: seven hours

    Seven-hour-area-under-the-curve of drowsiness on 100 mm visual analog scales will be determined

  2. Area-under-the-curve for dryness of the mouth

    Time frame: seven hours

    Seven-hour-area-under-the-curve of dryness of the mouth on 100 mm visual analog scales will be determined

Secondary outcomes

  1. Mean percent of time of reporting drowsiness on a dichotomous scale.

    Time frame: seven hours

    Mean percent of time of reporting drowsiness on a dichotomous scale will also be determined.

  2. Mean percent of time of reporting dryness of mouth

    Time frame: seven hours

    Mean percent of time of reporting dryness of mouth on a dichotomous scale will also be determined.

Sponsors and collaborators

Lead sponsor

King Faisal Specialist Hospital & Research Center

Other

Registry information

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Dec 29, 2011
Registry last updated
Mar 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.